Purchase Order 75N91019P00647

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $12,068.21, with an award date of September 12, 2019 and completion date of October 12, 2019. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to GenScript USA Inc. for $6,126.56 on July 28, 2017, for sequencing services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,823.88 on July 24, 2019. The order covers sequencing services at the awardee's location in Piscataway, New Jersey, with an ultimate completion date of August 23, 2019. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $14,558.16, issued on January 14, 2020, with final completion due February 12, 2020. Work is performed in Bethesda, Maryland. The order carries firm fixed pricing and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,663.10 on May 28, 2019, to procure custom gene synthesis, custom peptide synthesis, direct cloning, and plasmid services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of June 27, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $3,964.20 on September 5, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price structure and ultimate completion date of October 5, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,666.96 on June 28, 2017. Performance occurs in Piscataway, New Jersey. The order procures peptide services on a firm fixed price basis, with ultimate completion targeted for July 27, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,578.26 on June 11, 2019, covering custom gene synthesis, custom peptide synthesis, direct cloning, plasmid preparation, and crude peptide library services. No set-aside was used. Work is performed in Piscataway, New Jersey. The order was firm fixed price with an ultimate completion date of July 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $8,786.64 on August 15, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017. No set-aside category was applied.</p>